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the 1st-line biologic (EU:74%; US:70%) while 20% and 23% respectively in EU and 
US were on 2nd-line biologic. Per physician-assessment, 49%/41%/9% were mild/
moderate/severe in EU and 59%/35%/6% were mild/moderate/severe in US. Among 
those with available data, recent disease severity scores increased with increas-
ing Physician-assessment-based severity level in both EU and US (mean values for 
mild/moderate/severe): Tender Joint Count - EU:2.5/5.3/7.4 vs. US:2.3/6.6/8.9; Swollen 
Joint Count - EU:1.3/3.6/5.3 vs. US: 1.5/5.0/6.7; 100mm VAS Score - EU:19.8/38.9/51.4 
vs. US:17.2/47.0/48.6; HAQ Score - EU:0.8/1.4/1.5 vs. US:0.7/1.4/1.9; DAS28 score - 
EU:2.6/4.1/5.1 vs. US:2.5/4.0/5.3; Total Sharp Score - EU: 2.4/2.1/4.0 vs. US:3.1/2.3/7.0. 
Person correlation coefficient (r) comparing PGA (mild:1, modearate:2, severe:3) to 
individual objective disease severity measures were in the range of 0.79-1.00 in EU and 
0.77-1.00 in US. CONCLUSIONS: Across the geographies, physician-assessment (per 
clinical judgment) strongly correlated with the objective measures of disease severity 
among RA patients, further strengthening the argument towards continued inclusion/
use of simple physician-assessment scales in usual care practices around the world.
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OBJECTIVES: To compare RA patients on disease remission in the EU and US among 
those receiving a biologic treatment as part of usual care. METHODS: A multi-
country multi-center medical chart-review study of RA patients was conducted in 
4Q2011 among physicians (majority: rheumatologists) in hospitals/private practices 
to collect de-identified data on patients who were recently treated with a biologic 
as part of usual care. Physicians were screened for practice-duration and patient-
volume and recruited from a large panel to be geographically representative in the 
EU (UK/Germany/France/Italy/Spain) and US. For each study-eligible patient chart, 
physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status (incl. assessment of ‘disease remission’, per physi-
cian clinical judgment (both objective & subjective)). Patients on disease remission 
were analyzed. RESULTS: Analysis included 1161 and 405 patients experiencing 
disease remission in the EU and US respectively; 75% (vs. 74%), 20% (vs. 22%) and 
5% (vs. 4%) were on 1st line, 2nd line and > = 3rdline biologic respectively in the EU 
(vs. US). Mean duration in remission was: EU-12.2mo vs. US-12.1mo. Among those 
with lab measures, results were mostly similar between patients in remission in 
the EUvs.US: mean ESR(mm/h): 17.0vs.18.9, mean CRP(mg/dl): 7.0vs.1.6, Rheumatoid 
Factor (% positive): 83%vs.87% and Anti-CCP (% positive): 75%vs.74%. Among 
those with available data, recent (mean) disease severity scores were also similar 
between patients in remission in the EUvs.US: Tender Joint Count: 2.3vs.1.7, Swollen 
Joint Count: 1.2vs.0.8, 100mm VAS score: 18.6vs.18.9, HAQ: 0.7vs.0.6 and DAS28: 
2.6vs.2.2. CONCLUSIONS: This is one of the first studies to compare RA patients in 
remission in the EU and US; the characteristics of these RA patients in remission 
were found mostly similar between these geographic clusters, despite the potential 
variations in healthcare systems and modalities of care delivery, possibly attributed 
by ACR/EULAR efforts in standardizing the outcome definitions and care delivery.
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OBJECTIVES: To assess the patterns of disease remission among Rheumatoid 
Arthritis (RA) patients recently treated with biologic therapies in Japan. METHODS: 
A multi-center medical chart-review study of RA patients was conducted among 
physicians (rheumatologists) in hospitals/private practices to collect de-identified 
data on patients who were currently on a biologic or recently discontinued a bio-
logic within past 3-months. Physicians were screened for practice-duration and 
patient-volume and recruited from a large panel to be geographically representa-
tive of Japan. Patient charts of ~10 successive patients visiting each center/prac-
tice during study period were selected. Physicians abstracted patient diagnosis, 
treatment patterns/dynamics and patient symptomatology/disease status (incl. 
assessment of ‘disease remission’, per physician clinical judgment (both objective 
& subjective)). RESULTS: In 4Q2011, physicians abstracted 435 eligible RA patient 
charts; 79%, 17%and 3% were on 1st line, 2nd line and 3rd line biologic respectively. 
Overall, 49% of patients were in remission; the mean duration of remission sta-
tus was 16.7 months. Remission-rate differed by biologic lines: 1st-line:53%, 2nd-
line:41%, 3rd-line:21%. Among those with lab measures, results differed between 
those in remission vs. those who were not: mean ESR(mm/h): 18.1vs.30.6, mean 
CRP(mg/dl): 0.5vs.1.2, mean MMP3(ng/ml): 84.7-vs-136.7, Rheumatoid Factor (% 
positive): 87%-vs-91% and Anti-CCP (% positive): 91%-vs-94%. Among those with 
available data, recent (mean) disease severity scores differed between those in 
remission vs. those who were not: Tender Joint Count: 0.8-vs-2.7, Swollen Joint 
Count: 0.8-vs-2.6, 100mm VAS score: 12.8-vs-32.2, HAQ: 0.1-vs-0.2 and DAS28: 1.8-
vs-3.7. CONCLUSIONS: Approximately half of the patients were not in remission 
in this cohort of RA patients in Japan who were treated with a biologic; they experi-
enced disproportionate level of disease burden. As the line of treatment increased, 
proportion of individuals achieving remission decreased. These observed patterns 
warrant further scrutiny to determine the best practices and improve remission 
rates, thereby alleviating patient burden.
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effectively target interventions to improve arthritis management in the Medicare 
managed care population.
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OBJECTIVES: To describe prevalence and to evaluate pattern of use and sanitary 
costs of patients treated with osteoporosis drugs, using advanced reporting tools 
and methodologies integrating Big Data (coreReports) METHODS: Starting from 
ARNO Observatory, an Italian Database that collects health data on a population 
of 13 million Italian citizens, a new automated analytical tools (CoreReports) has 
been developed in order to manage, catalog and find the strategic indicators of 
healthcare costs and patients care pathways related to Diseases, Populations, Drugs 
with benchmarking among different geographical areas. All web-based Reports are 
automatically generated on-the-fly according to analytical needs and validated by 
a Scientific Committee with experts in various diseases. Among different diseases 
some results related to osteoporosis will be presented. RESULTS: Of the 5,364,167 
subjects over 40 years, 176,831 (prevalence 3.3%) were treated with osteoporosis 
drugs with the following pattern of use: bisphosphonates (80%), strontium ranela-
tum (18%), parathyroid hormone (1.2%), SERMs (0.8%), denosumab (0.4%). A consid-
erable percentage (21.8%) didn’t received vitamin D supplements in association. 
Patients with osteoporosis received many drugs expression of comorbidity (car-
diovascular drugs 67% of patients, corticosteroids 25%, nervous system drugs 33%). 
More than 1/6 of patients were hospitalized during 2012 (fractures 2,2%). Less than 
50% of patients controlled their serum calcium levels in the last three years, 34% per-
formed a densitometry. The average yearly cost/patient is 2.332€ , 37% due to drugs 
(30% specific drugs, 70% others), 45% due to hospitalization and 18.8% to lab tests 
and diagnostic examinations. CONCLUSIONS: Osteoporosis represents a condition 
of high epidemiological prevalence and with a strong impact on the social welfare, 
on prevention and on pharmaceutical costs. A big data infrastructure represents a 
tool to evaluate patient care pathways with osteoporosis and estimate cost of illness 
and can be a valid instrument to support clinical governance
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OBJECTIVES: Despite an estimated 2 million osteoporosis (OP)-related fractures occur-
ring annually, achievement of post-fracture OP quality measures is low. In 2013, the 
national average pass rate on the Healthcare Effectiveness Data and Information Set 
(HEDIS) measure “Osteoporosis Management in Women who had a Fracture” was 23%. 
This study has sought to identify characteristics associated with success or failure in 
meeting the current OP HEDIS measure. METHODS: Women were included if they 
were between 67-85 years (yrs) of age, had ≥ 1 fracture from July 2011 to December 
2013 (index date = earliest encounter), and were continuously enrolled in a Humana 
Medicare Advantage with Prescription Drug coverage (MAPD) plan for at least 12 
months pre-index and 6 months post-index. Patients were excluded if they had a 
BMD (bone mineral density) test or OP treatment pre-index. Descriptive statistics 
were compiled for the following variables: age, race, geographic region, and insurance 
type. RESULTS: The sample included 52,864 women. Mean age among the 17,952 (34%) 
patients who “passed” and the 34,912 (66%) who “failed” the HEDIS measure was 76.3 
yrs and 76.1 yrs respectively (p= 0.0003). A higher percentage of black women were 
in the “failed” group (6.2% failed vs. 5.4% passed; p< 0.0001), while Hispanic women 
were more prevalent in the “passed” group (3.0% passed vs. 1.3% failed; p< 0.0001). A 
larger proportion of patients residing in the Midwest were in the “failed” group (27.3% 
failed vs. 19.3% passed; p< 0.0001), along with those in suburban (26.5% failed vs. 19.6% 
passed; p< 0.0001) and rural (12.5% failed vs. 7.8% passed; p< 0.0001) areas. A greater 
fraction of women who “passed” the measure (69.9% passed vs. 60.6% failed; p< 0.0001) 
resided in the South. CONCLUSIONS: Preliminary results identify characteristics of 
women with OP who are receiving suboptimal care. Further analyses could enable 
targeting of at-risk women to improve post-fracture OP management.
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OBJECTIVES: To evaluate the relationship between physician-assessment (per clini-
cal judgment) and objective measures for disease severity assessments among RA 
patients in the EU and US. METHODS: A multi-country multi-center medical chart-
review study of RA patients was conducted in 4Q2011 among physicians (major-
ity: rheumatologists) in hospitals/private practices to collect de-identified data on 
patients who were recently treated with a biologic as part of usual care. Physicians 
were screened for practice-duration and patient-volume and recruited from a large 
panel to be geographically representative in the EU (UK/Germany/France/Italy/Spain) 
and US. For successive patients visiting each center/practice during study period, 
physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status incl. physician-assessment of disease severity (rated 
as mild/moderate/severe, per clinical judgment). RESULTS: In EU and US, 2208 and 
851 patient charts were abstracted respectively; majority of the patients were on 
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exceeding the FDA label recommendations of ADA 40 mg biweekly, ETN 50 mg 
weekly, and UST 45 mg every 12 weeks. RESULTS: In total, 15,400 PsA patients and 
40,545 PSO patients met the inclusion criteria. The number (proportion) of patients 
receiving increased maintenance doses for PsA was1,603 of 8,908 (18%) for ADA 
and 1,300 of 7,647 (17%) for ETN. The number (proportion) of patients receiving 
increased maintenance doses for PSO was 3,187 of 21,234 (15%) for ADA; 5,201 of 
16,318 (32%) for ETN; and 3,136 of 6,915 (45%) for UST. CONCLUSIONS: A large 
subgroup of patients treated with commonly used biologic agents is maintained 
on increased maintenance doses.
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OBJECTIVES: To describe one-year persistence with first-line biologic treatments 
(abatacept [ABA], adalimumab [ADA], certolizumab [CER], etanercept [ETN], 
golimumab [GOL], and infliximab [INF]) in a US managed care population with 
rheumatoid arthritis (RA). METHODS: This is a retrospective cohort study using 
administrative data for individuals in HealthCore Integrated Research Database 
(HIRDSM). The study cohort included patients initiating first-line biologics between 
Jul 2009 and Jan 2013 and was followed for one year since biologic initiation. The 
first biologic used following 6 months of continuous enrollment defined the index 
event. Non-persistence was defined as the absence of persistence, which entails at 
least one > 45-day gap in days of supply on their index agent or a biologic switch. 
Non-persistent patients were further categorized as switching, having a non-index 
biologic claim prior to or following the first gap; restarting, having an index bio-
logic claim after the gap; or discontinuation, no claims for any biologic following 
the gap. RESULTS: A total of 4,937 patients met the eligibility criteria (ABA:290, 
ADA:1,471, CER:132, ETN:2,331, GOL:184, INF:529; mean age:48.4, 76.7% female). 
45.2%, 42.3%, 32.6%, 45.0%, 33.7% and 46.7% patients on ABA, ADA, CER, ETN, GOL, 
and INF were persistent, respectively. GOL patients were the least likely to either 
persist or restart therapy (49.5%), followed by CER (56.1%), ADA (60.4%), ABA (61.4%), 
ETN (63.1%), and INF (64.3%). Switching rate was lowest for ABA (13.1%) and high-
est for GOL (18.5%). Discontinuation rate was lowest for INF (19.7%) and highest for 
GOL (32.1%). CONCLUSIONS: Overall, less than half of patients with RA on first-line 
biologics were persistent during the first year of therapy in this population. As low 
persistence may compromise treatment effectiveness, more research is needed to 
understand the reasons for non-persistence.
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OBJECTIVES: To estimate the length of gaps in reimbursement when an etanercept 
patient transitions from private to public plans, and describe their treatment 
patterns and lines of therapy. METHODS: A retrospective cohort of medication 
transaction data (IMS Brogan Lifelink® database) from Ontario and Quebec phar-
macies was analyzed. Patients were eligible if their last etanercept transaction 
from a private plan (index date) was between 01/01/2010 and 06/30/2013 and their 
first transaction from a public plan was within one year from the index date. The 
gaps in reimbursement were the difference between the index date plus days’ 
supply and the date of the first public etanercept transaction. RESULTS: Of 474 
patients included, 432 continued a DMARD or biologic in their public plan and 
397 had at least 1 year of follow-up from their first public claim. Patients were 
50% from Ontario, 40% male. 73% had rheumatoid arthritis (RA) and 70% were < 
65 years. 75% had a gap in reimbursement (median = 19 days). 25% had either 
no gap, or an overlap in dispensed prescriptions, while 9% stopped their therapy 
altogether. Of patients who continued etanercept therapy on a public plan, 45% 
had a gap in coverage that would be considered a clinically meaningful delay in 
treatment (> 21 days). For etanercept patients who continued therapy for at least 
1 year, 71% progressed to etanercept ± DMARD, 5% to another biologic ± DMARD, 
and 23% to a DMARD only as their first line public therapy. CONCLUSIONS: 
A clinically significant number of patients experienced a meaningful gap in 
etanercept coverage which can result in suboptimal clinical outcomes. Over 
20% of patients revert back to DMARD therapy on a public plan even after pre-
viously receiving a biologic. Almost 10% do not continue RA treatment on a 
public plan.
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OBJECTIVES: i) to provide an overview of the new Common Drug Review (CDR) 
evaluative process for SEBs by the Canadian Agency for Drugs and Technologies in 
Health (CADTH); ii) to illustrate the Canadian Drug Expert Committee (CDEC) rec-
ommendation from the first monoclonal antibody SEB (infliximab SEB; Inflectra) 
in Canada and how the recommendation compares with regulatory approval; 
and iii) if possible (depending on timing of listings) to highlight how the public 
reimbursement of infliximab SEB compares with that of the reference infliximab 
(Remicade). METHODS: CDR’s SEB submission procedures were retrieved from 
CADTH’s website in order to delineate its history. The CDR recommendation of 
the infliximab SEB was compared to Health Canada’s approved indications. The 
pan-Canadian Pharmaceutical Alliance website was examined for the status of 
the infliximab SEB for potential negotiation. Formulary listing statuses and public 
reimbursement criteria are to be retrieved from provincial and federal formularies 
OBJECTIVES: To assess clinical characteristics of RA patients considered biosimilar-
infliximab-suitable (when it becomes available) by their physicians, in comparison 
to those who were not considered infliximab-biosimilar-suitable in EU. METHODS: 
A medical chart-review study of RA patients was conducted among physicians 
(primarily rheumatologists) in hospitals/private practices in UK/France/Germany/
Italy/Spain (5EU) to collect de-identified data on patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status; physicians identi-
fied whether patient was biosimilar-infliximab-suitable (yes/no), and if yes, rated 
how likely would they prescribe biosimilar-infliximab to them when the product 
becomes available. Physicians were screened for practice-duration and patient-
volume and recruited from a large panel to be geographically representative. 
Consecutive patients currently on (or discontinued within past-3mo) biologic visit-
ing each center/practice during the screening period were selected for chart abstrac-
tion; analysis compared biosimilar-infliximab-suitable to those who were not (per 
physician judgment), excluding those who previously failed infliximab. RESULTS: 
731 patients (UK:166/France:110/Germany:66/Italy:190/Spain:199) were included 
in the analysis. 260 (36%; UK:47%/France:27%/Germany:38%/Italy:40%/Spain:26%) 
were identified as biosimilar-infliximab-suitable; of these, 58% were rated > = 5 
(scale:7(extremely likely)-1(not at all likely)) regarding likelihood of being prescribed 
biosimilar-infliximab. For biosimilar-infliximab-suitable Yes/No groups, mean age: 
50.5yrs/ 50.9yrs; Female:74% (both-groups); time since diagnosis: 70.2/84.1mo; 
mean # of lines of past biologic/oral-DMARD use: 1.2/1.3. Current drug class usage 
included (biosimilar-infliximab-suitable:Yes/No): biological-DMARD:96%/93%, non-
biological-DMARD:60%/63%, steroids:21%/28%, NSAIDs-COX2-inhibitors:11%/7%, 
NSAIDs- non-COX2-inhibitors:16%/11%, and analgesics:25%/12%. Percentage 
patients with moderate/severe disease (per physician judgment; biosimilar-inf-
liximab-suitable:Yes/No):49%/41%. Among those with available data, recent lab/
disease measures were (biosimilar-infliximab-suitable:Yes/No): ESR(23.3/22.7mm/h) 
and CRP(14.2/8.0mg/dl); HAQ(1.0/1.0), DAS28 (3.2/3.0), VAS(0-10scale; 3.8/3.6), Swollen 
Joint Count(3.2/2.1) and Tender Joint Count(5.3/3.2). CONCLUSIONS: Patients con-
sidered infliximab-biosimilar-suitable (per clinical judgment) had been in care for 
relatively shorter period, had higher disease severity and a lower percentage of them 
used steroids. Physicians were also not readily prepared to prescribe the biosimilar 
to all infliximab-biosimilar-suitable patients. Further scrutiny is warranted to under-
stand the drivers behind physician perception of biosimilar-infliximab-suitability.
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OBJECTIVES: To examine biologic use, health care costs, and medication effectiveness 
for patients initiating biologic DMARDs before vs. after a 2012 policy change imple-
mentation restricting receipt of adalimumab to patients who had previously failed 
another biologic. METHODS: Patients newly initiating a biologic from 01JAN2011-
30JUN2012, and continuously enrolled for 1 year before and after the initial biologic 
claim (index) were identified from a large geographically diverse US health plan affili-
ated with Optum. Patients with a claim for rheumatoid arthritis (RA), psoriasis, pso-
riatic arthritis, or ankylosing spondylitis were included. Total health care costs were 
examined in the 1-year post-index for all patients. Medication effectiveness at 1-year 
was assessed in patients with RA using a previously validated claims-based algorithm. 
Cost and effectiveness were examined comparing patients initiating a biologic before 
vs. after policy implementation (01JAN2011-30JUN2011 vs. 01JAN2012-30JUN2012). 
Total health care costs were inflation-adjusted using the 2013 CPI, and biologic cost 
was calculated using December 2013 WAC values. RESULTS: Of 46,668 patients treated 
with a biologic from 01JAN2011-30JUN2012, 4,181 met all selection criteria; 1,441 
and 1,330 patients newly initiated a biologic before vs after policy implementation. 
Adalimumab and etanercept accounted for 40.2% and 41.3% of new starts in 2011, 
respectively. In 2012 19.5% and 51.4% initiated adalimumab and etanercept, respec-
tively. The 2011 vs 2012 mean [median] total health care costs were $10,941 [$4,821] 
vs. $10,467 [$4,558] (p= 0.59) and the overall cost of all biologics were $25,328 [$25,361] 
vs. $24,783 [$25,307] (p= 0.26). The percentage of RA patients effectively treated in the 
2011 and 2012 cohorts was 25.6% vs. 25.0%, respectively (p= 0.78). CONCLUSIONS: 
Policy implementation resulted in a noticeable change in the proportion of patients 
treated with adalimumab and etanercept. Patients initiating therapy before and after 
policy implementation experienced similar total health care costs, biologic cost, and 
algorithm-defined medication effectiveness.
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OBJECTIVES: Psoriasis (PSO) and psoriatic arthritis (PsA) are immune-mediated 
inflammatory diseases. Therapeutic management may include use of biologic 
agents such as adalimumab (ADA), etanercept (ETN), and ustekinumab (UST). In 
clinical practice, patients may receive increased doses during the maintenance 
phase of treatment, exceeding the dosing recommended in FDA labels. The objec-
tive of this study was to assess the proportion of patients treated with ADA or ETN 
for PsA, and ADA, ETN, or UST for PSO who receive an increased maintenance 
dose. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient diag-
noses of PsA or PSO were selected from the Symphony PTD Claims Database if 
their first biologic prescription date (index date) fell between May 2010 and April 
2013. Patients were included if (1) full access was available to all pharmacy claims 
≥ 12 months before and ≥ 12 months after their index date, and (2) they were 
treatment-naive to the agent of interest pre-index. Treatment with a different 
biologic pre-index was not considered a reason for exclusion. Dosing was assessed 
over 12 months post-index. Increased maintenance doses were defined as doses 
